Phase 1 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a lung condition called IPF (idiopathic pulmonary fibrosis) by a lung specialist, using internationally recognised guidelines.
- People whose blood oxygen level, measured by a fingertip sensor after sitting quietly for at least 5 minutes, is 92% or higher.
- People whose lung capacity (measured by a breathing test called spirometry) is at least 40% of what would be expected for someone of their age, height, and sex.
Who may not be able to join:
- People who have had a sudden worsening of their IPF in the last 3 months.
- People who test positive for COVID-19 two days before entering the study facility.
- People who have been diagnosed with COPD (chronic obstructive pulmonary disease), or whose breathing test results show a certain pattern associated with airway obstruction.
- People who currently use oxygen overnight, at any amount or through any method (note: using oxygen during the day for short periods is allowed).
- People who have been diagnosed with a sleep breathing disorder, such as sleep apnea.
- People who have had a respiratory infection (in the nose, throat, or lungs) within the 8 weeks before entering the study facility.
- People who have a history of aspiration pneumonitis (a type of lung inflammation caused by inhaling food, liquid, or stomach contents).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chief Development Officer, Trevi Therapeutics
Phone: 203-654-3287
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Respiratory Function and Safety Assessed by Number of Participants With Increase in End Tidal Partial Pressure of Carbon Dioxide by Capnography (PetCO2) of at Least 10 Millimetres of Mercury (mmHg) From Baseline, or PetCO2>55 mmHg, for at Least 1 Minute; Respiratory Function and Safety as Assessed by Number of Participants With a Decrease in Blood Oxygen Saturation (SpO2) to <88% for at Least 1 Minute; Respiratory Function and Safety as Assessed by Number of Participants With a Decrease in Respiratory Rate (RR) to <6 Breaths per Minute; Safety and Tolerability as Assessed by Number of Particip...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.